Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Developing New Methods For Detecting Hepatotoxicity Signals

This article was originally published in The Pink Sheet Daily

Executive Summary

Current methods for detecting hepatotoxicity have no mathematical basis, Pfizer says. The company plans to evaluate patient data for Rezulin and Trovan, which were the subject of liver toxicity concerns.

You may also be interested in...

AstraZeneca Exanta Liver Toxicity Outweighs Benefit – FDA Advisory Cmte.

Cardiovascular & Renal Drugs Advisory Committee votes against recommending approval for all three indications AstraZeneca is seeking for the anticoagulant. The firm’s proposed risk management plan did not seem adequate to prevent severe liver injury, committee members agree.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Changes To The NHS: How Can Pharma Best Position Itself?

The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts